Dr. David Spigel on Collaborating to Identify the ‘Next Best Questions’

David R. Spigel, MD, a medical oncologist and the chief scientific officer at Sarah Cannon Research Institute who presented results from the phase 3 ADRIATIC trial during a plenary session at the 2024 American Society of Clinical Oncology Annual Meeting, discusses what he saw as the meeting’s key highlights.

“There’s been a lot of great news at [the annual meeting] in lung cancer, non-small cell and small cell, EGFR-mutated, ALK-rearranged lung cancer, but also in other areas like gastroesophageal cancer and melanoma,” he said.

Dr. Spigel highlighted how the annual meeting brings together people from across oncology to connect, learn, and build upon discoveries.

“These are great opportunities for everyone to learn about the advances that are being made, but also where we’re not making advances and where there’s more work to do,” Dr. Spigel said. “There’s really not a better opportunity for everyone to collaborate and begin thinking of the next best questions that need to be answered to help more patients in the world.”